These precision drugs are the biggest breakthroughs we’ve seen in decades for extending the lives of men with advanced prostate cancer.
Sue McDermott talks about her husband Bernie's commitment to new research, and how Christmas is different without him around.
Today, results released at the ESMO 2019 conference in Barcelona showed targeted breast and ovarian cancer drug olaparib could slow the progression of advanced prostate cancer. Find out how these advances are set to transform men’s lives.
BLOG: From 'seek and destroy' radiotherapy to repurposing an ovarian cancer drug, it's been a week of big news from the world's biggest cancer research conference. Dr Matthew Hobbs gives his perspective on the latest in prostate cancer and what needs to happen next.
BLOG: Dr Matthew Hobbs, our Acting Director of Research, shares his highlights from the latest research into more effective treatments for men with prostate cancer.
BLOG: Our research comms officer, Ruby Kell, explains how a promising new test we're funding could help identify men whose radiotherapy is likely to fail, then target them with a commonly-used drug that will stop the treatment from being thwarted.
Hayley Yarnley knows how much our new precision medicine research programme could have helped her father, Bernie, who died from advanced prostate cancer last December. She describes how the births of her children kept him going during his treatment, and why he was convinced scientists would one day find a cure.
The Institute of Cancer Research has discovered a genetic mutation in samples of some men's tumours that could make them particularly susceptible to immunotherapy treatment. The researchers are now committed to running clinical trials to prove if their theory is right.
A new study suggests olaparib could boost the efficacy of treatment for earlier-stage prostate cancer, after discovering how it can block the repair of DNA in cancer cells no matter what kind of the disease they have.
Prostate cancer is finally catching up with similar diseases in having treatments that can target an individual’s specific cancer – and it’s thanks to the game-changing research that you help us fund.